期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
IL-33与心脏移植免疫关系的研究进展 被引量:1
1
作者 左建峰 沈振亚 陈月秋 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2017年第4期567-570,共4页
白细胞介素33(IL-33)是IL-1家族成员,参与多种机体炎症与免疫反应过程。IL-33既可以通过增加Th2细胞和调节性T细胞(Treg)的比例在组织修复、器官移植和保持体内平衡中起重要作用,也可以通过增加Th1细胞比例从而增加免疫力。IL-33可以参... 白细胞介素33(IL-33)是IL-1家族成员,参与多种机体炎症与免疫反应过程。IL-33既可以通过增加Th2细胞和调节性T细胞(Treg)的比例在组织修复、器官移植和保持体内平衡中起重要作用,也可以通过增加Th1细胞比例从而增加免疫力。IL-33可以参与多种组织器官移植的免疫耐受,在心脏移植中,IL-33可以通过增加Th2细胞、Treg和髓源性抑制细胞(MDSC)的比例或增加抑制炎症的IL-4、IL-5和IL-10等细胞因子进行免疫调节,从而延长移植心脏的存活时间。本文主要对IL-33以及其与心脏移植免疫方面的研究进行综述。 展开更多
关键词 白细胞介素33(IL-33) 心脏移植免疫 间充质干细胞 免疫调节 综述
下载PDF
LncRNAs与心脏移植免疫研究进展
2
作者 孟颖琦 张烁 《心血管病学进展》 CAS 2019年第4期626-629,共4页
心脏移植是心脏疾病终末阶段最有效的治疗方法,心脏移植后能否长期存活依然是一个挑战,移植排斥是影响移植物存活的主要障碍,早期发现亚临床排斥可显著提高移植排斥的诊断并对及时指导调整排斥药物治疗剂量有重要意义。长链非编码RNAs(l... 心脏移植是心脏疾病终末阶段最有效的治疗方法,心脏移植后能否长期存活依然是一个挑战,移植排斥是影响移植物存活的主要障碍,早期发现亚临床排斥可显著提高移植排斥的诊断并对及时指导调整排斥药物治疗剂量有重要意义。长链非编码RNAs(lncRNAs)是长度>200个氨基酸的非编码RNAs,调节基因表达分化和发育过程。LncRNAs在心脏移植中存在差异表达并可能参与调节免疫反应和移植结果,有可能成为心脏移植状态标志物和改善移植结果的新治疗目标。现就近年来lncRNAs在心脏移植中研究进展做简要综述。 展开更多
关键词 LncRNAs 心脏移植免疫 移植排斥 移植耐受
下载PDF
Orthotopic heart transplantation with prolonged donor ischemic time:report of 3 cases and literature review
3
作者 Zhang Zaigao Xie Shuiben Xue Zhiqiang Bei Yajun Zhao Zhe 《Journal of Medical Colleges of PLA(China)》 CAS 2009年第4期235-238,共4页
Heart transplantation has become an effective therapy for patients with end stage heart failure. The preservation of the donor heart is an important factor that affects the results of the operation. We performed 3 cas... Heart transplantation has become an effective therapy for patients with end stage heart failure. The preservation of the donor heart is an important factor that affects the results of the operation. We performed 3 cases of orthotopic heart transplantation and obtained some experience in the preservation of the donor heart. Methods: Three male patients with end stage heart failure received the operation in our department successfully. Doppler echocardiography showed left ventrieular end diameter (LVED) of the patients were 91, 87, and 83 mm, and ejection fraction (EF) were 24%, 20%, 12.9%, respectively. Once the declaration of brain death had been made, the median stemotomy was performed with a sternal saw. Haparin at a dose of 300 U/kg of body weight was administered. After at least 2-min heparin circulation, the procurement proceeded. The superior vena cava and the inferior vena cava were nearly completely divided. When the heart was empty, the ascending aorta was cross-clamped and the St. Thomas solution was infused by gravity. The heart was excised by transection of the inferior vena cava, the superior vena cava and all pulmonary veins. After donor heart was removed, it was infused with University of Wisconsin (UW) solution by gravity at a temperature of 4-6℃, then placed in UW solution for storage during transportation. The temperature of solution was maintained at about 4-6℃. The ischemic times of donor heart were 9, 8 and 6 h, respectively. The bicaval anastomotic heart transplantation was adopted. The left atrial anastomoses were constructed using 3.0 polypropylene. The inferior vene cava anastomosis was constructed, the donor and native aorta were cut to an appropriate length. Then the aorta and main pulmonary artery anastomosis were performed respectively. The superior vene cava anastomosis was usually constructed during the rewarming phase. The intraoperative course with a cardiopulmonary bypass of the 3 patients was 96, 44 and 49 min, respectively. Standard triple immunosuppression therapy was commenced in the immediate post-operative period. Results: The operation procedure was smooth and no perioperative death occurred. The follow-up was carried out carefully. The patient's condition was fine in 25, 30 and 32 months after operation. The blood pressure was 130/90, 140/95 and 120/80 mmHg, respectively, and LVED was 51, 49 and 53 mm; EF was 50%, 54% and 60%, respectively. Cardiothoracic ratio was 0.63, 0.55, and 0.64, respectively. Conclusion: Preservation time of donor heart with St. Thomas solution infusion and UW solution storage at 0-4℃ may exceed 6 h, and receive comparable middle-term outcomes. 展开更多
关键词 Heart transplantation Dilated cardiomyopathy Myocardial protection Donor heart preservation
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部